Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 29, 2011 Brian Orelli	What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key.
The Motley Fool July 12, 2011 Luke Timmerman	Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug.
The Motley Fool June 20, 2011 Brian Orelli	See Drug, Approve Drug An approval of Regeneron's macular degeneration Eylea looks likely.
The Motley Fool August 20, 2011 Luke Timmerman	Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas.
The Motley Fool July 13, 2011 Brian Orelli	2 Questions for Seattle Genetics So far the FDA is fairly impressed with Seattle Genetics' lymphompa drug brentuximab vedotin.
The Motley Fool September 27, 2010 Brian Orelli	Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin.
The Motley Fool June 16, 2011 Brian Orelli	No Poke in the Eye Here What's the biggest sign that the Food and Drug Administration is all set to approve Regeneron Pharmaceuticals' Eylea? The briefing documents for the advisory committee contained a proposed version of the label.
The Motley Fool July 15, 2011 Brian Orelli	Seattle Genetics Will Work It Out This isn't the NFL labor negotiations.
The Motley Fool July 10, 2008 Brian Lawler	Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks.
The Motley Fool July 5, 2011 Luke Timmerman	Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high.
The Motley Fool September 28, 2011 Brian Orelli	One Step Closer to an FDA Decision Cell Therapeutics is still risky, though.
The Motley Fool March 31, 2011 Brian Orelli	Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles.
The Motley Fool July 14, 2011 Luke Timmerman	Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel An FDA panel of cancer drug experts recommended in a 10-0 vote that the company's drug for Hodgkin's lymphoma should be cleared for sale in the U.S.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool November 29, 2011 Brian Orelli	Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away.
The Motley Fool December 19, 2011 Brian Orelli	ARIAD's Prolific 2011 The biotech is doing something right.
The Motley Fool October 12, 2010 Brian Orelli	Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.
The Motley Fool January 14, 2008 Brian Lawler	Score One for Dendreon and Disclosure A prestigious journal supports Dendreon's potential prostate cancer treatment, and makes a compelling case for more FDA disclosure.
The Motley Fool January 22, 2008 Brian Lawler	Seattle Genetics' Fortuitous Timing The drugmaker raises some much-needed cash with a $90 million stock offering.
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool June 16, 2011 Brian Orelli	Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA.
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
The Motley Fool September 2, 2011 Brian D. Pacampara	Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients.
The Motley Fool April 14, 2009 Brian Orelli	Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
The Motley Fool October 14, 2011 Sean Williams	7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma...
The Motley Fool February 29, 2008 Brian Lawler	Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease.
The Motley Fool October 11, 2010 Brian Orelli	FDA Rejection, but Still Jazzed Up Sometimes, biotechs are like that.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool February 4, 2009 Brian Orelli	Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval.
The Motley Fool January 6, 2011 Brian Orelli	$145 Million Down; Billions to Go Seattle Genetics signs up another partner.
The Motley Fool April 2, 2008 Brian Lawler	Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders.
The Motley Fool February 9, 2007 Brian Lawler	Picking Up the Pace at Seattle Genetics The cash situation shows the shares of this drug development company could be appealing.
The Motley Fool March 17, 2008 Brian Lawler	The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool October 19, 2010 Brian Orelli	Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency.
The Motley Fool February 10, 2009 Brian Orelli	Roses and Candy From the FDA? Some drugmakers expect the FDA to bestow its kiss of approval this month. Read on to see who.
The Motley Fool November 23, 2011 Brian Orelli	I Was Wrong About Dendreon But maybe not in the long term.
The Motley Fool September 14, 2010 Brian Orelli	This Bad News Could've Been Worse A Seattle Genetics drug fails, but there's more in the pipeline.
The Motley Fool April 11, 2008 Brian Lawler	Amgen's Unsurprising Delay The FDA extends its review of an Amgen drug candidate.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
The Motley Fool May 9, 2007 Brian Lawler	Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note.
The Motley Fool March 10, 2010 Brian Orelli	Up 160% With Room to Run You've got to love biotech and InterMune.
The Motley Fool September 10, 2008 Brian Lawler	A Pfizer Drug With a Cloudy Future The company offers another drug with mixed odds to the FDA.
The Motley Fool March 19, 2007 Brian Lawler	Is Dendreon Doomed? A pivotal FDA regulatory meeting approaches for the development-stage pharma. Investors, take note.
The Motley Fool September 9, 2010 Brian Orelli	Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September.